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Anti-tau conformational scFv MC1 antibody
efficiently reduces pathological tau species
in adult JNPL3 mice
Francesca Vitale, Luca Giliberto, Santiago Ruiz, Kristen Steslow, Philippe Marambaud and Cristina d’Abramo*
Abstract
Tau, the main component of the neurofibrillary tangles (NFTs), is an attractive target for immunotherapy in Alzheimer’s
disease (AD) and other tauopathies. MC1/Alz50 are currently the only antibodies targeting a disease-specific
conformational modification of tau. Passive immunization experiments using intra-peritoneal injections have
previously shown that MC1 is effective at reducing tau pathology in the forebrain of tau transgenic JNPL3 mice.
In order to reach a long-term and sustained brain delivery, and avoid multiple injection protocols, we tested the
efficacy of the single-chain variable fragment of MC1 (scFv-MC1) to reduce tau pathology in the same animal
model, with focus on brain regional differences. ScFv-MC1 was cloned into an AAV delivery system and was
directly injected into the hippocampus of adult JNPL3 mice. Specific promoters were employed to selectively
target neurons or astrocytes for scFv-MC1 expression. ScFv-MC1 was able to decrease soluble, oligomeric and
insoluble tau species, in our model. The effect was evident in the cortex, hippocampus and hindbrain. The
astrocytic machinery appeared more efficient than the neuronal, with significant reduction of pathology in areas
distant from the site of injection. To our knowledge, this is the first evidence that an anti-tau conformational scFv
antibody, delivered directly into the mouse adult brain, is able to reduce pathological tau, providing further
insight into the nature of immunotherapy strategies.
Introduction
In Alzheimer’s disease (AD), neurofibrillary pathology
positively correlates with cognitive decline, emphasizing
the direct link between pathological tau accumulation
and neurodegeneration [8, 9, 30, 39, 50]. Several studies
show efficient reduction of tau pathology in transgenic
animal models, using an immunotherapeutic approach,
with different yields depending on the targeted epitopes
[3, 6, 7, 12, 14, 16, 17, 45, 52, 53]. Indeed targeting total tau,
tau phosphorylation or conformational epitopes might re-
sult in different outcomes, in terms of efficiency and safety.
Tau conformational change, targeted by the MC1 anti-
body, is one of the earliest detectable events in the brain of
AD patients. MC1 and Alz50 are the only tau antibodies tar-
geting the AD-specific epitope formed by two discontinuous
portions of tau, 7EFE9 and 313VDLSKVTSKC322 [21, 28, 29].
This aberrant conformation of tau was shown to be present
in a soluble form of the protein and in paired helical fila-
ments (PHF) assemblies [47]. Importantly, the level of MC1
reactivity correlates with the severity and progression of AD
[27]. From a therapeutic perspective targeting this tau struc-
tural modification is a very attractive approach to pursue. In
conventional passive immunotherapy studies performed in
mice, we and others [14, 17] have previously shown that tar-
geting the MC1 epitope can efficiently reduce neurofibrillary
pathology in forebrain, highlighting the importance of tau
epitope specificity: the ability to discriminate between
normal tau and pathological tau species confers MC1 a
remarkable advantage as immunotherapeutic tool com-
pared to pan-tau and phospho-tau antibodies, which on
the contrary might interfere with the normal function
of tau. Of note, humanized MC1 (LY3303560) has recently
entered a Phase II study to treat early symptomatic
Alzheimer’s disease [ClinicalTrials.gov, accession num-
ber NCT03518073].
The main challenge in neuro-therapeutic development
in humans is a successful delivery of molecules into the
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brain parenchyma. The first obstacle in this process is
crossing the blood brain barrier (BBB) and achieving wide-
spread brain diffusion of the drug [40]. In addition to low
tissue/cell penetration, using whole monoclonal antibodies
(mAbs) might result in potential serious adverse effects
such as inflammatory reactions and cerebral microhemor-
rhages [5, 44, 49]. Finally, the relative short half-life of
conventional mAbs poses a question of long term sustain-
ability of such treatments, with need for repeated infusions,
and issues of compliance and cost. Hence, the need to de-
velop new and safer tools for passive tau immunotherapy.
Antibody engineering represents an important alternative
approach to increase brain penetration, while limiting the
deleterious effects of an uncontrolled immune response.
Most recently, a study [32] showed that, in vivo and in cul-
tured neurons, antibody effector function (i.e. Fc region) is
not required for targeting and clearing tau with specific
mAbs; reducing the effector function may offer a safer
approach for targeting tau by avoiding engagement of
microglia that may induce an inflammatory response
but still achieving clearance of pathological tau. Further-
more, a recent study using AAV-vectored intracerebral
passive immunization with the anti-phospho-tau mono-
clonal antibody PHF1 (tau pSer396/404) [35] was proven
efficacious in adult P301S mice in reducing insoluble
pathological phosphorylated tau (p-tau) in the hippocam-
pus, with some reduction of p-tau immunoreactivity in
the cortex. Also, an anti-pan-tau single chain variable frag-
ments antibody (scFv) [26] was shown to reduce soluble
tau pathological species in specific hippocampal regions in
9 month old mutant P301S injected at birth. In line
with these findings, we have engineered MC1 as scFv to
target tau in the brain of adult JNPL3 mice. ScFv are
the smallest antibody fragments containing a complete
antigen-binding site, consisting of the light and heavy-
chain variable domains covalently joined by a polypep-
tide linker and lacking the Fc region [2, 4, 25, 51]. In
order to sustain the expression of antibody fragments
over long periods, scFv-MC1 has been cloned in the
adeno-associated viral vector serotype 5 (AAV5) and
delivered by a one-time intracranial injection [10, 11,
19, 23, 24, 33]. Here we show that scFv-MC1 is actively
expressed and released in the extracellular milieu upon
AAV5-vectored hippocampal injection, exerting its effect
also in areas distant from the site of injection. Moreover,
in this system we are able to target either neurons or as-
trocytes, and we show that the astrocytic machinery works
more efficiently at reducing soluble, oligomeric and insol-
uble tau species in different brain areas.
Materials and methods
ScFv-MC1 design, expression and purification
The MCLAB antibody service (San Francisco, CA) was
employed in order to sequence the light and heavy-chain
variable domains corresponding to the MC1 antibody.
The service provides RNA extraction from hybridoma cell
pellets and transcription into cDNA, followed by amplifi-
cation of the heavy and light chains using degenerate vari-
able heavy (VH) and variable light (VL) chains primers.
The VH and VL chains were joined together by a 15 amino
acid residues linker (Gly4Ser)3. 5’-terminal signal pep-
tide (SP) and 3’-terminal Myc and His6X tags were added
(Fig. 1a). ScFv-MC1 was cloned into the mammalian ex-
pression vector pcDNA3.1 (Genewiz, South Plainfield,
NJ). HEK293T were seeded 24 h prior to transfection
on 6-well plates, at a density of 400,000 cells/well. Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA) was used for
transfection, with 0.5 μg of pcDNA3.1 encoding scFv-
MC1. After 48 h, the scFv-MC1 released into the condi-
tioned medium was affinity purified using a Ni-Sepharose
High Performance column (GE Healthcare, Port Washing-
ton, NY). The efficiency of purification was tested using the
same immunosorbent assay employed to assess the anti-
gen–binding specificity of the scFv (described below). Start-
ing material, flow through and eluted fractions were tested
to check for proper enrichment of the purified material.
The purified scFv-MC1 was checked on Coomassie-stained
SDS-PAGE gel for proper molecular weight.
ScFv-MC1 antigen-binding specificity
The scFv antigen-binding reactivity was measured using an
immune-sorbent assay where 96-well plates were coated
over-night (O/N) with Neutravidin (Sigma-Aldrich, Saint
Louis, MO), followed by incubation with the MC1 spe-
cific 998-biot peptide (GenScript, Piscataway, NJ). Purified
scFv-MC1, MC1, DA31 and CP13 (negative controls)
were diluted in 5% non-fat milk and added to the wells.
After incubating for 1 h at room temperature (RT), mouse
anti-His6Xtag Ab was added (1:1000 dilution) (Thermo
Fisher Scientific, Waltham, MA) followed by goat anti-
mouse IgG-HRP (1:1000 dilution) (SouthernBiotech,
Birmingham, AL). Bio-Rad HRP Substrate Kit (Bio-Rad la-
boratories, Hercules, CA) was used for the detection and
plates were read with an Infinite m200 plate reader
(Tecan, San Jose, CA) at 415 nm.
Adeno-associated viral vector (AAV) serotype and cellular
selectivity
The AAV packaging and purification service was provided
by Vector Biolab (Malvern, PA). ScFv-MC1 was sub-cloned
into the adeno-associated viral vector serotype 5 (AAV5)
under the control of either the synthetic strong CAG
(CMV-chicken beta actin-rabbit beta globin) or the
GFAP (glial fibrillary acidic protein) promoter. In order
to enhance expression of the transgene, the WPRE
Woodchuck hepatitis virus (WPRE) post-transcriptional
regulatory element was added 5’ of the Myc and His6X
tags. AAV5-scFv-MC1 (CAG or GFAP promoter) or
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AAV5-eGFP (enhanced green fluorescent protein under
CAG or GFAP control expression) was injected at a
dose of 2X1010 GC per hemisphere.
Transgenic mice and stereotaxic injections
JNPL3 mice obtained from Taconic (Germantown, NY)
express 0N4R human tau with the P301L mutation that
causes frontotemporal dementia in humans, under the
mouse prion promoter. JNPL3 mice develop NFTs as early
as 4.5 months and in later stages progressive deterioration
of the motor function.
Intra-hippocampal injections of AAV vectors were
performed according to a stereotaxic surgery protocol
previously published [13]. Under sterile conditions,
three month-old JNPL3 mice were anesthetized and se-
cured on a stereotaxic frame (David Kopf instruments,
Tujunga, CA). Mice received bilateral hippocampal injec-
tion of AAV preparations using a neuro syringe with a 33
gauge needle (Hamilton, Reno, NV). Injections were per-
formed using the following coordinates: AP-2.1 from
bregma, ML +/− 2.0 from bregma, DV-1.8 below dura.
After injection, the needle was left in place for 5 min to
Fig. 1 ScFv-MC1 design, expression and characterization. a scFv-MC1 diagram: 5’-terminal signal peptide (SP), variable heavy (VH) and variable
light (VL) chains joined together by a 15 amino acid residue linker (Gly4Ser)3, and 3’-terminal Myc and His6X tags. b HEK293 cells were transiently
transfected with empty vector (empty v.) or scFv-MC1. In the cell lysate (immunoblotting) the scFv-MC1 was detected as a 30 kDa band; c in the
conditioned medium the presence of scFv-MC1 was assessed using a specific ELISA and was expressed as ODs (optical densities). Cells transfected
with the empty vector did not show any sign of reactivity in western blotting or ELISA. d Purified scFv-MC1, run on SDS-PAGE gel and stained with
Coomassie: two different purified preparations (1, 2) revealed the expected molecular weight (30 kDa). e scFv-MC1 antigen-binding specificity: purified
scFv-MC1 tested for its activity on the specific peptide (998b) was compared to the MC1 mAb, showing a comparable reactivity; CP13 and DA31 were
used as negative controls. f Representative images of AD brain immunohystochemistry: both scFv-MC1 and MC1 (1:500 dilution) showed specificity for
the neurofibrillary pathology (Olympus BH-2 microscope, bar: 50 μm)
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minimize backflow and then slowly removed. Mice were
housed individually for 2 weeks to completely recover
from surgery. Animals were treated according to the
current regulations for the proper handling of research an-
imals, following an approved IACUC protocol.
Pilot injections were performed in non-transgenic ani-
mals (C57BL/6) in order to evaluate general tolerance: no
weight loss or motor changes were detected at 6 weeks
post-injection (n = 10).
Female JNPL3 mice (n = 18) were used to validate the
AAV5-scFv-MC1 expression system in brain (injected at
3 month of age and sacrificed 4 weeks later). In addition,
the efficacy study was performed on 45 females JNPL3
(n = 15 per group): mice were injected at 3 month of
age and sacrificed four months later. Overall 73 mice
were employed in this study.
Brain extracts preparation
Four months after the intracranial injection, mice were
sacrificed by isoflurane overdose, decapitated and proc-
essed as described previously [17]. The brain was removed
and divided at the midline so that just one half of the brain
was dissected for biochemical analysis. The cortex, hippo-
campus and hindbrain were homogenized separately using
an appropriate volume of homogenizing buffer, a solution
of Tris-buffered saline (TBS), pH 7.4, containing 10 mM
NaF, 1 mM Na3VO4 and 2 mM EGTA, plus the complete
Mini protease inhibitor cocktail (Roche, Indianapolis, IN).
Supernatants were analyzed for protein concentration
using DC Protein Assay (Bio-Rad Laboratories). Brain ho-
mogenates were stored at − 80 °C and used for separate
measurement of soluble and insoluble tau. Soluble tau was
measured as heat-stable preparation (hsp) from brain. Hsp
were prepared by adding 5% ß-Mercaptoethanol and
200 mM NaCl to the brain homogenates. Samples were
then heated at 100 °C for 10 min and cooled at 4 °C for
30 min. After centrifuging at 14,000 g in a table-top micro-
centrifuge at 4 °C for 15 min, supernatants were collected
and 5X sample buffer (Tris-buffered saline, pH 6.8 contain-
ing 4% SDS, 2% beta-mercaptoethanol, 40% glycerol and
0.1% bromophenol blue) was added. To obtain insoluble
tau preparations (INS), homogenates were thawed and
spun at 14,000 g for 10 min at 4 °C. The collected superna-
tants were centrifuged at 200,000 g for 30 min at room
temperature (RT); the pellets were then re-suspended in
homogenizing buffer and centrifuged again at 200,000 g
for 30 min at 25 °C. The final pellets were re-suspended in
1X sample buffer and heated at 100 °C for 10 min to effi-
ciently dissociate the insoluble tau fraction.
Tau ELISAs
Levels of total and phosphorylated tau were assessed
using the Low-tau ELISA protocol previously published
[1, 22]. 96-well plates were coated for 48 h at 4 °C with
specific purified monoclonal tau antibodies (DA31, CP13,
PHF1, RZ3) at a concentration of 6 μg/ml. After washing,
plates were blocked for 1 h at RT using StartingBlock buf-
fer (Thermo Fisher Scientific, Waltham, MA). Brain sam-
ples and standards were diluted in 20% SuperBlock buffer
(Thermo Fisher Scientific) in 1XTBS and loaded on the
plates. Once the samples were added, the total tau detec-
tion antibody DA9-HRP, diluted 1:50 in 20% SuperBlock
in 1XTBS, was added to the samples and tapped to com-
bine. Plates were then incubated overnight at 4 °C. Next
day, 1-Step ULTRA TMB-ELISA (Thermo Fisher Scien-
tific) was added for 30 min at RT, followed by 2 M H2SO4
to stop the reaction. Plates were read with Infinite m200
plate reader (Tecan, San Jose, CA) at 450 nm.
Immunoblotting
An aliquot of the total lysates was used for immunoblot-
ting. 0.1% SDS was added to the lysates, followed by sonic-
ation (3 cycles, 10 s each). Samples were run on 4–20%
Criterion Tris-HCl gels (Bio-Rad Laboratories) and elec-
trophoretically transferred to a nitrocellulose membrane
(Thermo Fisher Scientific). Residual protein-binding sites
were blocked by incubation with 5% non-fat milk in
1XTBST (1X TBS plus 0.1% Tween 20) 1 h at RT,
followed by an O/N incubation at 4 °C with primary anti-
bodies diluted in 20% SuperBlock buffer (Thermo Fisher
Scientific) in 1XTBST. Mouse anti-N-Cadherin A60 (BD,
Franklin Lakes, NJ), mouse anti-actin Ab5 (BD) were di-
luted 1:5000; anti-Myc-tag 9B11 (Cell Signaling, Danvers,
MA) was diluted 1:1000. Appropriate isotypes secondary
antibodies HRP-conjugated were diluted 1:2000 in 5%
non-fat milk 1XTBST, and added for 1 h at RT. Every step
was followed by 3 or 4 washes in 1X TBST. Detection was
performed using Pierce ECL Western Blotting Substrate
(Thermo Fisher Scientific) or SuperSignal West Dura ex-
tended duration substrate (Thermo Fisher Scientific) and
exposed to x-ray films.
Immunocytochemistry, immunofluorescence and image
analysis
Tau staining [17] and immunofluorescence were per-
formed according to standardized protocols. After de-
capitation, half of the brain was fixed overnight in 4%
paraformaldehyde at 4 °C. Serial sections were cut from
the fixed brain half on a vibratome, conserved in TBS
(50 mM Tris, 150 mM NaCl, pH 7.6)/0.02% NaN3, and
stained on 24-well plates with a panel of tau antibodies
and an anti-Myc-Tag (9B11) mouse mAb (Cell Signaling).
Endogenous peroxidases were quenched with 3% H2O2/
0.25% Triton X-100/1XTBS for 30 min. Non-specific
binding was blocked with 5% non-fat milk-1XTBS for
1 h at RT. Primary antibodies were used as follows: anti
tau antibodies CP13 and PHF1 (1:5000), RZ3 and MC1
(1:500) and anti-Myc-Tag (1:1000) all diluted in 5%
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non-fat milk-1XTBS, and incubated O/N at 4 °C, shaking.
Human AD brains were stained with MC1 and
scFv-MC1 both at 1:500 dilutions. Biotin-conjugated
secondary antibodies (SouthernBiotech, Birmingham, AL)
directed against the specific isotypes were diluted 1:1000
in 20% SuperBlock, left for 2 h at RT, and lately
Streptavidin-HRP (SouthernBiotech) was incubated for
1 h. Staining was visualized by 3,3’-Diaminobenzidine
(Sigma-Aldrich).
For immunofluorescence, sections were pre-incubated
5 min at RT in 1XPBS (Gibco, Carlsbad, CA) containing
0.2% TritonX100 (Sigma-Aldrich). After blocking 1 h at
RT with a solution containing 5% normal goat serum
(Sigma-Aldrich) diluted in 1XPBS/0.1%Triton, sections
were incubated with primary antibodies diluted in 1% nor-
mal goat serum in 1XPBS/0.1% Triton: NeuN 1:1000
(EMD Millipore, Burlington, CA) MAP2 1:1000 (EDM
Millipore), anti-Myc-Alexa555 1:500 (EMD Millipore),
GFAP 1:1000 (Cell Signaling). After washing 3X in 1XPBS/
0.1%TritonX100, Alexa Fluor secondary antibodies − 488,
− 568, − 633 (Invitrogen, Carlsbad, CA) were added at
1:1000 dilutions for 1 h at RT, in different combinations in
order to obtain multiple labeling images. DAPI (Invitrogen)
was used to counterstain. Brains slices were then mounted
on slides and let dry 20 min before being cover-slipped
using Vectashield hard set anti-fade mounting (Vector
Laboratories, Burlingame, CA).
Images were acquired using Olympus BH-2 bright field
microscope (Waltham, MA), Zeiss Axio Imager Apotome
and Zeiss 880 confocal laser miscroscopes (Peabody, MA).
The acquisition parameters were kept the same for all
conditions and images were analyzed and processed using
ImageJ/Fiji software (NIH) and Photoshop CS6 software
(Adobe). Semi-quantification was done on the hippocam-
pal quadrant CA1 and on the entorhinal cortex by using
the measure particles tool, working with 8-bit images and
adjusting the threshold.
Tau and anti-scFv-MC1 antibodies detection in serum
A detailed protocol was previously published to detect
total tau in serum [18]. Upon sacrifice mice were bled,
samples collected and allowed to clot for 30 min at RT.
After cooling for 15 min, samples were spun at 14,000 g
for 10 min at 4 °C; supernatants were collected and then
re-spun at 14,000 g for 5 min at 4 °C. The final superna-
tants correspond to the serum samples. In order to de-
tect tau in serum, samples were diluted 1:3 in 0.2 M
NaOAc, pH 5.0 and heated at 90 °C for 15 min. After
the heat treatment, samples were allowed to cool at
4 °C for 15 min, and then spun at 15,000 g for 10 min.
Supernatant were collected and 1 M Tris buffer was added
to neutralize the pH. After diluting 1:2 in 20% Superblock,
samples were loaded on the total tau ELISA (DA31
capture).
In order to detect antibodies directed to the scFv-MC1,
96-well plates were coated with purified scFv-MC1 at
6 μg/ml for at least 24 h. Plates were washed 3X and
blocked for 1 h using StartingBlock (Thermo Fisher Scien-
tific). Plates were washed 5X and 50 μl of sera added in
triplicate at 1:1000 dilution in 20% SuperBlock (Thermo
Fisher Scientific). After 1 h incubation plates were washed
5X and 50 μl of goat anti-mouse non-specific IgG HRP-
conjugated (SoutherBiotech) was added and incubated for
1 h. Finally, Bio-Rad HRP Substrate Kit has been used for
the detection and plates were read with Infinite m200
plate reader (Tecan) at 415 nm.
Statistical analysis
Quantitative data were analyzed using the dedicated soft-
ware GraphPad Prism vs6 (GraphPad software Inc., CA).
One-way ANOVA was performed when the parametric as-
sumption of normality (D’Agostino-Pearson omnibus test)
was accomplished. When not, non-parametric Kruskal-
Wallis was performed instead. Statistical significance was
set at P < 0.05. Error bars represent the SEM. Linear re-
gression analysis was performed for all correlations.
Results
ScFv-MC1 is efficiently secreted in vitro, and its antigen-
binding specificity is comparable to the MC1 parent
antibody
ScFv-MC1 was expressed in the HEK293T cell line in
order to assess for efficient secretion in medium. The
scFv was detected in cell lysates (Fig. 1b) and condi-
tioned medium of the HEK293T after 48 h of transient
transfection (Fig. 1c). Taking advantage of the His6X-tag
added at the 3’-end of the DNA construct, the recombin-
ant antibody was purified using a Ni-Sepharose column.
Coomassie-stained SDS-PAGE gel was used to confirm
molecular weight (around 30 kDa) and purity of the prep-
arations (Fig. 1d). The scFv-MC1 antigen-binding reactiv-
ity was measured against an MC1 specific peptide (Fig. 1e)
and shown to be as specific as the parent antibody. To
complete its characterization, purified scFv-MC1 was
employed to stain AD human brains, confirming its
specificity in binding NFTs similarly to the parent MC1
antibody (1:500 dilution) (Fig. 1f ).
AAV5-scFv-MC1 transduces neurons and astrocytes in vivo,
under the CAG or the GFAP promoters respectively
We selected the AAV5 serotype for our in vivo experi-
ments, given its ability to transduce various brain cellular
populations and providing efficient transgene expression
under different promoters [10, 11, 19]. To start the in vivo
study, unilateral hippocampal injection of AAV5-scFv-
MC1 was performed in 3 month old JNPL3 mice, with the
transgene under the expression of the strong CAG
promoter. Four weeks after the injection, brains were
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harvested following biochemical or immunofluorescent
analysis. As shown in Fig. 2a, scFv-MC1 was detected
along the whole hippocampus following intracranial
injection; no signal was detected in non-injected mice.
Immunoblotting analysis was performed in order to
confirm the scFv expression in the hippocampi: as
shown in Fig. 2b, scfv-MC1 was detected as a 30KDa
band in the treated animals, confirming the ability to
specifically express the recombinant antibody in vivo. Of
note, no reduction in the amount of neural-cadherin
(N-cadherin) was detected in these brains (Fig. 2b), imply-
ing no significant neurotoxicity at this time point.
In order to optimize the in vivo system and screen for
neuronal or astrocytic targeting, 3 month old JNPL3 mice
were injected in the hippocampus using AAV5 expressing
the transgene under the CAG or the GFAP promoters.
Four weeks after the injection, mice were sacrificed and
brains stained with multiple markers to track for cellular
expression, showing neuronal body localization when
employing the CAG promoter (Fig. 3a-e) and overall
astrocytic selectivity when the GFAP promoter was
used (Fig. 3f-j).
ScFv-MC1 diffuses into the brain parenchyma
After accurately monitoring for scFv-MC1 expression in
vivo, one-time intracranial bilateral injection of AAV5-
CAG-scFv-MC1 or AAV5-GFAP-scFv-MC1 was performed
in 3 months old JNPL3 mice, which were sacrificed four
months later. To assess for proper scFv-MC1 release in the
brain parenchyma, we tracked the recombinant tau anti-
body using an anti-Myc-tag antibody followed by DAB
staining. When comparing the whole hippocampus from
control animals (Fig. 4a) to the treated groups (Fig. 4h, o), a
marked staining was observed as the result of a strong re-
lease of scFv-MC1 in the extracellular milieu. As proof of
sustained production and efficient diffusion in the brain
parenchyma after 4 months, we show that the recombinant
antibody scFv-MC1 is detected not only at the site of injec-
tion (CA1/CA2 of hippocampus) (Fig. 4h, i, o, p) but also
in the subiculum (Fig. 4j, q), the dentate gyrus (DG)
(Fig. 4k, r), the entorhinal cortex (EC) (Fig. 4l, s) and in
other areas of the cortex (Fig. 4m, t), after expression
by either neurons or astrocytes. Of note, faint immuno-
staining is evident in the hindbrain with either systems
(Fig. 4n, u). We then performed immunoblotting ana-
lysis, pulling together three representative samples from
each treatment group (Fig. 4v): cortex, hippocampi and
hindbrain homogenates from the scFv-MC1 injected
groups show presence of the recombinant antibody,
demonstrating production and/or diffusion of the anti-
body in the brain parenchyma. The amount of scFv-MC1
detected in the cortex and hindbrain was lower than in
the site of injection (hippocampus), and required a larger
amount of loading material on gels and enhanced expos-
ure in order to get a detectable signal. The expression
levels of the neural-cadherin (N-cadherin) were used as
readout of neuronal integrity four months after scFv-MC1
treatment.
MC1-tau and pThr-231 immunoreactivity are significantly
reduced in the hippocampus and entorhinal cortex upon
astrocytic expression of scFv-MC1
As a proof of concept for the current immunotherapeutic
approach, MC1 immunohistochemical analysis was per-
formed (Fig. 5a-i) followed by assessment of pathology in
the CA1 quadrant (Fig. 5j) of the hippocampus and the
entorhinal cortex (Fig. 5k). In both regions, a significant
reduction of MC1-tau was detected in the astrocytic-
driven expression group (GFAP-scFv) compared to the
non-treated mice.
In order to address the question as to whether targeting
MC1-tau could affect the build-up of tau phopsho-epi-
topes, brain staining was performed showing a substantial
reduction of phosphorylated tau at Thr-231 (RZ3) in both
Fig. 2 AAV5-scFv-MC1 transduction in vivo. a Representative images
of JNPL3 mice brain sections, 4 weeks post injection (n = 6): the
AAV5-scFv-MC1 injected brain showed clear expression of the
recombinant antibody in the hippocampus using an anti-Myc antibody
(red). Nuclei were stained with DAPI (blue). No signal was detected in
the not injected brains (Zeiss Axio Imager Apotome, bar: 500 μm).
b western blotting on hippocampus lysates of injected (Inj.) or not-
injected (Not Inj.) JNPL3 mice, using anti-Myc antibody. Neuronal
N-cadherin was used as a marker of neuronal integrity, and actin
was used as a housekeeper
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treatment groups compared to non-treated controls
(Fig. 6a-c eGFP expression; Fig. 6d-f neuronal scFv-MC1
expression; Fig. 6g-i astrocytic scFv-MC1 expression).
Quantification was performed on the CA1 quadrant of the
hippocampus (Fig. 6j) and on the entorhinal cortex (EC)
(Fig. 6k), showing a significant decrease in pThr-231 when
the transgene was expressed under the GFAP astrocytic
promoter. A trend of reduction is also evident in the CAG
injected group for both MC1 and RZ3 staining (Fig. 5j-k,
6j-k). When immunohistochemical analysis was performed
with PHF1 (pSer396/404) and CP13 (pSer202), no signifi-
cant differences were observed in treated and non-treated
animals (not shown). TUNEL and Iba1 staining have so far
failed to show any evidence of cell death or differential
microglia activation between treated and non-treated mice,
again arguing against any toxicity (not shown).
Phosphorylated soluble tau is significantly reduced in the
hippocampus, cortex and hindbrain following scFv-MC1
injection
Three different cerebral regions were dissected upon
sacrifice: hippocampus, cortex and hindbrain. Biochem-
ical analysis of soluble tau, by ELISA, showed reduction
of phosphorylated tau at the Thr231 residue. In the
hippocampus (Fig. 7a), soluble phospho-tau Thr231 was
significantly reduced when the astrocytic promoter GFAP
was employed. Consistent with the previously anticipated
parenchymal diffusion of scFv-MC1 from the site of injec-
tion, tau phosphorylated at Thr231 was significantly re-
duced in the cortex (Fig. 7b) and hindbrain’s soluble
fractions (Fig. 7c), with the GFAP promoter displaying
again the more significant effect. Cortical total soluble
tau was reduced with either promoter (Additional file 1:
Figure S1d), as seen before in the whole forebrain frac-
tions [17].
Oligomeric/aggregated tau is significantly reduced in the
hippocampus and hindbrain upon astrocytic expression
of the scFv-MC1
Taking advantage of our tau mono-ELISA [22], we have
analyzed the amount of oligomeric/aggregated species in
the lysates belonging to the different brain areas. Tau ag-
gregated forms in the hippocampus were significantly
decreased when the scFv-MC1 was under neuronal or
astrocytic expression (Fig. 7d), again with the astrocytic
promoter being more efficient. In the cortex, a trend to-
wards reduction is seen (Fig. 7e). Aggregated tau in the
hindbrain was significantly reduced only when targeting
the astrocytic population to release scFv-MC1 (Fig. 7f ).
Insoluble tau is reduced in the HB and cortex
Analysis of the insoluble fraction was performed on cor-
tex and hindbrain. In our protocol, due to the technical
requirement to obtain the insoluble tau fraction, i.e. the
need for a sufficient amount of tissue, this analysis was
not performed on the hippocampus. Instead, as shown
above, the tau mono-ELISA was used as a functional
surrogate of insoluble tau.
As shown in Fig. 7h, a reduction of total insoluble tau
in the hindbrain was seen in the astrocytic expression
group. While no effect was detected on total insoluble tau
in cortex (Fig. 7g), analysis of different phosphorylation
Fig. 3 AAV5-scFv-MC1 cellular selectivity. Representative immunofluorescent confocal images of the hippocampus (CA1 quadrant) from JNPL3 mice.
a-e When mice were injected with AAV5-CAG-scFvMC1 (n = 6), the scFv was expressed mainly in neurons: scFv-MC1 (a, Myc-red), MAP2-positive
neurons (b, green), GFAP-positive astrocytes (c, magenta); co-localization is shown as merge of red and green (e, orange/yellow). f-j Upon injection
with AAV5-GFAP-scFvMC1 (n = 6), scFvMC1 was expressed primarily in astrocytes: scFv-MC1 (f, Myc-red), GFAP-positive astrocytes (g, green),
NeuN-positive neurons (h, magenta); co-localization is shown as merge of red and green (j, yellow). Nuclei were stained with DAPI (blue, panel d and
i). Images represent maximum-intensity projection of z-stacks (Zeiss 880 confocal laser miscroscope, bar: 50 μm)
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residues showed a significant decrease of insoluble cortical
tau phosphorylated at Thr231, together with a trend to-
ward reduction of the other phospho-epitopes in both
areas (Additional file 1: Figure S2a-f), again more pro-
nounced with the GFAP promoter.
Discussion
In an effort to overcome the limitations of conven-
tional immunotherapy, including the need for multiple
administrations, we engineered scFv-MC1, cloned it
into an AAV vector, and delivered it to the brain via
one-time bilateral intracranial injection, to achieve sus-
tained production and release of the antibody. Here we
show that: 1) scFv-MC1 shares the same specificity of
the parent MC1 antibody; 2) AAV5-vectored scFv-MC1
can be efficiently expressed by neurons or astrocytes; 3)
scFv-MC1 can spread from the site of injection to adjacent
brain structures; 4) scFv-MC1 is able to reduce/prevent
Fig. 4 Brain parenchyma expression and diffusibility. ScFv-MC1 is expressed and released in the extracellular milieu: anti Myc-tag staining performed
4 months after the one time intracranial injection with AAV5-eGFP (a-g) (n = 15), AAV5-CAG-scFvMC1 (h-n) (n = 15) and AAV5-GFAP-scFvMC1
(o-u) (n = 15). Representative images from the whole hippocampus (Olympus BH-2 bright field microscope, bar: 500 μm), CA1, subiculum,
dentate gyrus (DG), entorhinal cortex (EC), frontal cortex and HB (bar: 100 μm). The scFv is visualized as a brown signal and shows extensive
expression in hippocampi from treated mice, with spreading in areas distant from the site of injection. (v) Immunoblot analysis of lysates from
the hippocampus, cortex and hindbrain: AAV5-eGFP injected (1), AAV5-CAG-scFMC1 injected (2), AAV5-GFAP-scFvMC1 injected (3). Three
representative lysates from each group of treatment were pulled together and loaded on SDS-PAGE (40μg proteins of hippocampus; 300μg
proteins of cortex; 150μg proteins of HB plus HRP substrate enhancer when developing). Anti Myc-tag was used to track the scFv in the brain
parenchyma; actin was used as a housekeeper and N-cadherin as a marker of neuronal integrity. Of note, immunoblots images shown represent
optimal exposure samples to visualize differences within the brain areas
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tau pathology in JNPL3 adult mice, even in sites distant
from injection, with efficacy on different tau species
(soluble, oligomeric, insoluble), and more notably with
astrocytic production.
We selected two different cellular populations to express
and secrete the engineered scFv-MC1. In our study, the
astrocytic system was overall more efficient at reducing
pathological tau species in adult JNPL3 mice. The effect
was not directly related to the amount of scFv released in
the extracellular milieu. In fact, both systems expressed a
comparable amount of recombinant antibody in the
hippocampus and cortex. In the hindbrain, a location far
from the injection site, we detected more scFv-MC1 when
using the neuronal system, by biochemical analysis. It is
still unclear whether this is due to a better diffusivity of
the antibody to the HB or to a higher expression by the
stronger CAG promoter. A higher presence of scFv-MC1
in the HB did not result in more robust reduction of tau
pathology in this area. Further studies of the expression/
diffusion of scFv through the brain parenchyma are
needed to understand this complex dynamic.
In this study, we performed an accurate and extensive
biochemical analysis of soluble, oligomeric and insoluble
tau species in the hippocampus, cortex and HB, showing
a consistent pattern of reduction of pathological tau upon
treatment with our recombinant antibody. A decrease in
soluble pThr231 was common to the three brain areas
analyzed upon astrocytic expression of the scFv-MC1
(hippocampus: − 35%; cortex: -25%; HB: -33%), while
no major effects were detected on other soluble tau/
phosphorylation residues (CP13: Ser202; PHF1: Ser396–
404) (Additional file 1: Figure S1). Supporting these data,
we found that the pThr231 immunoreactivity in the
hippocampus and EC was significantly reduced in the
injected mice (hippocampus: − 60% circa; EC: − 70%
circa), consistent with the reduced tau-MC1 immuno-
staining (hippocampus: − 60% circa; EC: − 70% circa).
Immunostaining using CP13 and PHF1 confirmed the
previous findings (not shown). We believe that the gen-
eral selectivity for the Thr231 epitope is related to the
fact that when our treatment first begins we are target-
ing soluble tau and its early modifications, e.g. Thr231.
Upon binding soluble MC1-tau, the recombinant anti-
body appears to be able to selectively reduce/prevent
the buildup of soluble pThr231-tau as well.
Soluble oligomeric tau represents a transition state
between physiological soluble and pathological insol-
uble tau aggregates. To detect oligomeric tau, we used
Fig. 5 MC1-tau immunoreactivity. Representative images of MC1 staining on JNPL3 brains. a, b, c Non-treated mice received AAV5-eGFP injection.
Treated mice were injected with AAV5-CAG-scFvMC1 d, e, f or AAV5-GFAP-scFvMC1 g, h, i (Olympus BH-2 bright field microscope; bar:
500 μm a, d, g; bar: 100 μm b, c, e, f, h, i). j Quantification of percentage of area stained by MC1 shows a significant reduction in the AAV5-GFAP-scFvMC1
injected group, in the CA1 region of hippocampus (*P = 0.0320 by non-parametric Kruskall-Wallis test) and k in the EC (**P = 0.0025 by one-way
ANOVA followed by Dunnett’s post hoc test). AAV5-CAG-scFvMC1 injected mice only showed a non-significant trend reduction in MC1 staining in (j)
CA1 (p = 0.3999) and in k EC (p = 0.2626). All graphs are means +/− SEM (n = 15 in each group of treatment)
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a mono-ELISA [22]. This assay allows the detection of
aggregated tau species, ranging from dimers to larger
aggregates, and represents a good marker of progres-
sion towards the formation of neurofibrillary pathology
in tau transgenic animal models. The percentage of de-
crease of oligomeric tau was calculated to correspond
to a 40% and 45% reduction, in the hippocampus and
HB respectively. No effect was detected in the cortex.
Since these species mostly belong to the soluble pool of
tau, we estimated, in our control group, the percentage
of oligomeric species relative to the whole tau soluble
fraction for each separate brain region: 1% in the hippo-
campus, 0.5% in the cortex and 3.5% in the HB. We believe
that this component resembles the soluble tau species re-
cently described by Takeda et al. [46]. This group has
shown that PBS-soluble phosphorylated high-molecular-
weight tau species are axonally transported and passed on
to synaptically connected neurons. These species have been
described as globular but non-fibrillar structures, account-
ing for only a small fraction of all soluble tau species, esti-
mated at < 10% in mutant-tau rTg4510, similar to our data.
Interestingly, these structures also have a pathological
misfolded conformation, positive for the Alz50/MC1
antibody [46]. We speculate that scFv-MC1 binds these
soluble globular aggregated structures, lowering their
total amount, most likely in the extracellular milieu,
hence blocking their further spreading.
As for oligomeric tau, the total insoluble fraction was
unchanged in the cortex and reduced in the HB. The
48% reduction of insoluble tau in the HB overlaps the
45% reduction of the oligomeric species in the same
area. Hence, in this “prevention protocol”, we assume that
the decreased accumulation of fibrillar aggregates is a con-
sequence of the reduced build-up of the oligomeric species.
This assumption is supported by the fact that tau levels in
serum are unchanged (Additional file 1: Figure S3), making
the peripheral sink hypothesis, as a mechanism of clear-
ance of the insoluble aggregates, unlikely. Considering the
data on hippocampal oligomeric/aggregated tau (DA9/
DA9 assay), we speculate that a similar reduction of insol-
uble tau is present in this area as well. More studies are
needed to clarify if, by employing a “therapeutic protocol”
treating mice at more advanced stages, we will achieve
clearance of established tau pathology.
In our estimate, the brain concentration of scFv-MC1
obtained by intracranial injection is in good excess to
Fig. 6 Tau phospho-immunoreactivity. Representative images of RZ3 (pThr231 tau) staining on JNPL3 brains. a, b, c Control mice received AAV5-eGFP
injection (n = 15). Treated mice mice were injected with AAV5-CAG-scFvMC1 (n = 15) (d, e, f) or AAV5-GFAP-scFvMC1 (n = 15) (g, h, i) (bar:
500 μm a, d, g; bar: 100 μm b, c, e, f, h, i). j Quantification of percentage of area stained by RZ3 shows a significant reduction in the AAV5-GFAP-scFvMC1
injected group, in the CA1 region of hippocampus (**P= 0.0026 by one-way ANOVA) and (k) in the EC (**P = 0.0069 by one-way ANOVA). AAV5-
CAG-scFvMC1 injected mice only showed a non-significant trend reduction in RZ3 staining in (j) CA1 (p = 0.0753) and in (k) EC (p = 0.1916). All
graphs are means +/− SEM and were analyzed by one-way ANOVA, followed by Dunnett’s multiple comparison post hoc test, comparing every
column to the eGFP injected group: **P < 0.01
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the amount of tau to target. Nevertheless, our results
show a partial reduction of build-up, or clearance, of tau
pathological species. Simply aiming at one tau epitope
might not be enough to reduce all pathology. Also, as
suggested in the neuronal delivery system, increasing the
“dose” of scFv-MC1 in mice might not be the solution,
Fig. 7 Soluble, oligomeric and insoluble tau. a, b, c Phosphorylated soluble tau levels (hsp: heat stable preparation) in the hippocampus, cortex
and HB: pThr231 tau was significantly reduced in the hippocampus (*P = 0.036 by one-way ANOVA) and cortex (*P = 0.0351 by one-way ANOVA)
when the astrocytic system was employed (GFAF-scFvMC1); in the cortex, a trend towards reduction was observed when neurons were targeted
(CAG-scFvMC1, P = 0.0614); in the HB, pThr231 was reduced with either promoter (CAG-scFvMC1 *P= 0.0237, GFAP-scFvMC1 *P= 0.0408 by one-way
ANOVA). d, e, f Oligomeric/aggregated tau species quantified in hippocampus, cortex and HB: oligomeric tau was significantly decreased in the
hippocampus both under neuronal (**P = 0.004 by one-way ANOVA) or astrocytic expression (***P = 0.0004 by one-way ANOVA); oligomeric
tau in the HB was significantly reduced only when using the GFAP-scFvMC1 system (*P = 0.0444 by one-way ANOVA); no modulation of
oligomeric tau species was found in the cortex. g, h Insoluble tau (INS) was analyzed in the cortex and HB: no changes were detected in the
cortex, while the HB showed a significant reduction under the expression of the GFAP promoter (*P = 0.0378 by non-parametric Kruskall-Wallis
test). All graphs are means +/− SEM (n = 15 in each group of treatment)
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in this tau over-expressing model. Targeting multiple epi-
topes, e.g. adding total tau or other phosphorylation spe-
cific antibodies to scFv-MC1, may result in a more
effective synergistic approach. More studies are needed to
explore this possibility. Of note, scFv-MC1 was not de-
tected in serum, by neither immunoblotting or ELISA
(data not shown), as already reported by others [26].
The usefulness of adeno-associated viruses as a gene de-
livery system has been extensively used in clinical trials, in-
cluding via intracranial administration [31, 34, 36, 38, 41,
42, 48]. Even though they are generally known for low
levels of immunogenicity [54], AAV’s efficacy could be
limited if the viral transduction per se led to a significant
alteration of the normal function of the tissue under ob-
servation, or to the activation of the host immune system
with the production of neutralizing antibodies (NAB) di-
rected to the transgene [15, 20, 37, 43, 54]. In our study,
the levels of inflammation (not shown) and neuronal in-
tegrity were assessed, and are negligible. Also, antibodies
directed to scFv-MC1 were found in plasma of few ani-
mals upon sacrifice (Additional file 1: Figure S4a), suggest-
ing an immunogenic response to the scFv (or a fragment
thereof). However, considered the success at reducing sol-
uble, oligomeric/aggregated and insoluble tau in different
brain regions, together with the correlation analysis data
generated (Additional file 1: Figure S4b, c), we believe that
the anti-scFv-MC1 do not affect efficacy, hence are so far
irrelevant in this study.
Conclusions
Overall, our results are encouraging for tau-directed scFv
immunotherapy, and are a good premise for translational
applications. AAV peripheral administration might be a
viable option, if penetration of the BBB or constitution
of a peripheral scFv “factory” are achieved. These will
be the scope of our further studies.
Additional file
Additional file 1: Figure S1. Total and phosphorylated soluble tau in
hippocampus, cortex and HB. (a, b, c) In the hippocampus, total tau was
not modulated, as well as the pSer202 and pSer396–404 phospho-epitopes.
(d, e, f) In the cortex, a significant reduction of total soluble tau was reached
with both the CAG (*P = 0.0325 by one-way ANOVA) and the GFAP pro-
moter (**P = 0.006 by one-way ANOVA). (g, h, i). In the HB, phosphorylation
at Ser202 was significantly decreased in the GFAP-scFMC1 treatment group
(*P = 0.0112 by one-way ANOVA). Error bars indicate means +/− SEM.
Figure S2. Phosphorylated insoluble tau (INS) in cortex and HB. (a, b, c)
Phosphorylation levels of insoluble tau in the cortex: the pThr231 residues
showed a significant reduction (*P = 0.0398 by non-parametric Kruskall-
Wallis test) in the GFAP expressed group, while pSer202 (P = 0.0685) and
pSer396–404 (P = 0.0649) showed a non-significant trend towards reduction
in the same treatment cohort. (d, e, f) In the HB, no significant decrease in
phosphorylated insoluble tau was detected, with a trend to reduction on
pSer396–404 in the GFAP-scFv treated group (P = 0.0768). Error bars indicate
means +/− SEM. Figure S3. Tau levels in serum. At sacrifice, total tau was
analyzed in serum (ng/ml), showing no significant difference between
groups. Figure S4. Antibodies directed to the scFv-MC1, in serum. (a) At
sacrifice, few animals in both groups of treatment were positive for the
presence of anti-scFv-MC1. (b) Linear regression analysis: in the neuronal
expression group (CAG promoter) no significant correlation was detected
between the concentration of anti-scFvMC1 antibodies in the serum
(ug/ml) and the concentrations of the oligomeric/aggregated tau in
hippocampus (r2 = 0.095). (c) In the astrocytic expression group (GFAP
promoter) the same analysis was performed, again with no significant
correlation between anti-scFvMC1 antibodies and oligomeric/aggregated
tau in hippocampus (r2 = 0.018). (PDF 851 kb)
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